TriangleNCT01170663 · CITED IN SOURCE DOCUMENTS
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2019-09-18
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Overall Survival Time (OS)
Progression-Free Survival (PFS)
Time to Progressive Disease (TTP)
Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD
Percentage of Participants With CR or PR (Objective Response Rate [ORR])
Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity)
Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion
Cmax After 4th Ramucirumab (IMC-1211B) Infusion
Cmax After 7th Ramucirumab (IMC-1211B) Infusion
Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion
Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion
Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion
Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status
Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score
Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Signed informed consent * histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma * Metastatic disease or locally advanced, unresectable disease * Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline) * Organs are functioning well (liver, kidney, blood) * Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1 Exclusion Criteria: * First line chemotherapy for metastatic gastric cancer other than platinum/fluoropyrimidine doublet with or without anthracycline * Previous systemic therapy with other anti-angiogenic drugs * Uncontrolled high blood pressure * Symptomatic or poorly controlled heart disease or had a heart attack or stroke within the last 6 month * Evidence of central nervous system (CNS) metastasis at baseline
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Ramucirumab (IMC-1211B) DP and Paclitaxel
- intervention Names
- Biological: Ramucirumab (IMC-1211B) DP
- Drug: Paclitaxel
- label
- Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
- type
- EXPERIMENTAL
- description
- Placebo and Paclitaxel
- intervention Names
- Drug: Placebo
- Drug: Paclitaxel
- label
- Placebo and Paclitaxel
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
- description
- 8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
- name
- Ramucirumab (IMC-1211B) DP
- other Names
- LY3009806
- IMC-1211B
- type
- BIOLOGICAL
- arm Group Labels
- Placebo and Paclitaxel
- description
- Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
- name
- Placebo
- type
- DRUG
- arm Group Labels
- Placebo and Paclitaxel
- Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
- description
- Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
- name
- Paclitaxel
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- DOUBLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 665
- type
- ACTUAL
Registered outcome plans (not posted results)
- other Outcomes
- description
- Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
- measure
- Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died
- time Frame
- Baseline up to 103 weeks and within 30 days of last dose of study drug
- primary Outcomes
- description
- OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.
- measure
- Overall Survival Time (OS)
- time Frame
- Randomization up to 27.5 months
- secondary Outcomes
- description
- PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause. PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization. Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment. Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy. Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.
- measure
- Progression-Free Survival (PFS)
- time Frame
- Randomization up to 22.2 months
- description
- TTP was defined as the time from randomization until date of radiographic progression using RECIST v1.1 criteria. PD was defined as having a ≥20% increase in sum of longest diameter (LD) of target lesions and at minimum 5 millimeters (mm) increase above nadir. Participants who did not progress or were lost to follow-up were censored at the date of last tumor assessment. Participants who had no baseline tumor assessment or no post baseline assessment and no death reported with 2 scan intervals post randomization were censored at date of randomization. Participants with no progression and not died within 2 scan intervals after last assessment were censored at date of last tumor assessment. Participants with no post baseline assessment or tumor progression but death reported within 2 scan intervals after randomization were censored at date of death.
- measure
- Time to Progressive Disease (TTP)
- time Frame
- Baseline up to 22.2 months
- description
- BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir. SD was defined as small changes that did not meet above criteria.
- measure
- Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD
- time Frame
- Randomization up to 22.2 months
- description
- ORR was the percentage of participants who had CR or PR defined using RECIST v1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions. PR was defined as having a ≥30% decrease in sum of LD of target lesions. Percentage of participants calculated as: (number of participants with CR + PR)/(total number of participants)\*100.
- measure
- Percentage of Participants With CR or PR (Objective Response Rate [ORR])
- time Frame
- Randomization up to 22.2 months
- description
- Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.
- measure
- Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity)
- time Frame
- Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks
- measure
- Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 1, Day 1, 1 hour post end of infusion (28-day cycles)
- measure
- Cmax After 4th Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)
- measure
- Cmax After 7th Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 4, Day 1, 1 hour post end of infusion (28-day cycles)
- description
- This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered. Cmin was not analyzed.
- measure
- Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 1, Day 1 predose (28-day cycles)
- measure
- Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 2, Day 15 (28-day cycle)
- measure
- Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion
- time Frame
- Cycle 4, Day 1 (28-day cycles)
- description
- EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains \[physical, role, cognitive, emotional, and social\], 9 symptom scales \[fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties\] and global health status scale). 28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale. A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.
- measure
- Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status
- time Frame
- Baseline, end of therapy (up to 103 weeks)
Full study description
- brief Summary
- This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
- detailed Description
- The aim of this study is to determine if paclitaxel given together with ramucirumab (IMC-1211B) as second line therapy will prolong overall survival (OS) compared to paclitaxel alone. Approximately 663 participants (at least 18 years) in approximately 200 study centers and in approximately 30 countries will be randomized with histologically or cytologically confirmed metastatic gastric or gastroesophageal junction adenocarcinoma. Participants must have received at least one cycle of first line therapy with any platinum/fluoropyrimidine doublet with or without anthracycline (epirubicin or doxorubicin) and must have discontinued this therapy prior to study entry due to disease progression. Upon registration and completion of screening procedure and reviewing the Inclusion and Exclusion Criteria eligible participants will be randomized to receive either paclitaxel plus ramucirumab or paclitaxel plus placebo. Ramucirumab (IMC-1211B) DP/placebo will be administered IV on Days 1 and 15, paclitaxel will be administered IV on Days 1, 8 and 15 of a 4 weekly cycle. Participants will be continuously treated and monitored until radiographic or symptomatic progression of disease, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.
Source references
- references
- citation
- Ogata T, Narita Y, Wainberg ZA, Van Cutsem E, Yamaguchi K, Piao Y, Zhao Y, Peterson PM, Wijayawardana SR, Abada P, Chatterjee A, Muro K. Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. J Gastric Cancer. 2023 Apr;23(2):289-302. doi: 10.5230/jgc.2023.23.e15.
- pmid
- 37129153
- type
- DERIVED
- citation
- Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387.
- pmid
- 34795131
- type
- DERIVED
- citation
- Yamaguchi K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Omuro Y, Tamura T, Piao Y, Homma G, Jen MH, Liepa AM, Muro K. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clin Drug Investig. 2021 Jan;41(1):53-64. doi: 10.1007/s40261-020-00979-3. Epub 2020 Dec 23.
- pmid
- 33355909
- type
- DERIVED
- citation
- Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh SC, Folprecht G, Ananda S, Girotto G, Wainberg ZA, Miron MLL, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist. 2021 Mar;26(3):e414-e424. doi: 10.1002/onco.13623. Epub 2020 Dec 23.
- pmid
- 33274542
- type
- DERIVED
- citation
- De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019 Aug;15(23):2723-2731. doi: 10.2217/fon-2019-0243. Epub 2019 Jun 25.
- pmid
- 31234645
- type
- DERIVED
- citation
- Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.
- pmid
- 30557792
- type
- DERIVED
- citation
- Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.
- pmid
- 28716815
- type
- DERIVED
- citation
- Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. doi: 10.1093/annonc/mdv625. Epub 2016 Jan 7.
- pmid
- 26747859
- type
- DERIVED
- citation
- Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016 Jul;19(3):927-38. doi: 10.1007/s10120-015-0559-z. Epub 2015 Oct 28.
- pmid
- 26510663
- type
- DERIVED
- citation
- Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
- pmid
- 25240821
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-2f3dd88913587360d018
- requested nct id
- NCT01170663
- primary nct id
- NCT01170663
- source kind
- fda_spl_label
- source record id
- 161cb5e7-7955-45e5-bdde-9be94fdbe76a
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- e1e9ed95f896182e63a6f141bf74bf7f70f406e5a0d2c1708af551370cf1f691
- payload
- application numbers
- BLA125477
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-2f3dd88913587360d018
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01170663
- occurrences
- context exact
- atified Log-rank p-value <0.001 Figure 1: Kaplan-Meier Curves for Overall Survival in REGARD Figure 1 RAINBOW The efficacy of CYRAMZA was evaluated in RAINBOW (NCT01170663), a multinational, randomized, double-blind study in patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the GEJ) who prev
- end
- 2772
- exact text
- NCT01170663
- start
- 2761
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/72/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 161cb5e7-7955-45e5-bdde-9be94fdbe76a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 8b976ba12932042765823e0997b9bfba65f6d17d93c7789d351e39674335679f
- spl effective time
- 20260609
- spl set id
- c6080942-dee6-423e-b688-1272c2ae90d4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e80887c53586b0442060
- requested nct id
- NCT01170663
- primary nct id
- NCT01170663
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 20f13c5c62ce6ffbb2dafce9a99993b62ee853964501fae15509a2830b8349c2
- payload sha256
- c86c488d42fd7d0b3387083d79e61e30e4c3eca4d22533d277936a562c1f994c
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e80887c53586b0442060
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01170663
- occurrences
- context exact
- tients with cisplatin- or 5-FU‒refractory, stage IV, gastric cancer.</p></li><li>In the international, double-blinded, phase III <a href="/clinicaltrials/NCT01170663">RAINBOW</a> trial (NCT01170663), 665 patients were randomly assigned to receive paclitaxel (80 mg/m<span class="sup">2</span>) on days 1, 8, and 15 every 28 d
- end
- 131954
- exact text
- NCT01170663
- start
- 131943
- context exact
- 8210;refractory, stage IV, gastric cancer.</p></li><li>In the international, double-blinded, phase III <a href="/clinicaltrials/NCT01170663">RAINBOW</a> trial (NCT01170663), 665 patients were randomly assigned to receive paclitaxel (80 mg/m<span class="sup">2</span>) on days 1, 8, and 15 every 28 days with either ramucirumab (8 m
- end
- 131986
- exact text
- NCT01170663
- start
- 131975
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/b520476df769e6fecd.html
- source file sha256
- 20f13c5c62ce6ffbb2dafce9a99993b62ee853964501fae15509a2830b8349c2
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:22.075850+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 93e6df01e9e806a0673bf0152a2eeeb828353c1de1fb5bdf86185aac466f15f4
- source title
- Gastric Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 21, 2025
- datetime
- 2025-02-21T12:00:00Z
- display
- February 21, 2025
Preserved source evidence · Not medical advice